BIOLOGICAL AGENTS IN MEDICAL THERAPY

  • N. V. Lysenko
  • A. Y. Kartvelishvili
Keywords: clinical pharmacology, biological agents

Abstract

Presented clinical pharmacology of biological products under the ATC classification system. The classifi­cation, characteristics of pharmacodynamics of drugs. An algorithm for the use of biological agents in thera­peutic practice: rheumatology, gastroenterology, neurology. Examined in detail the absolute and relative con­traindications and side effects of biological agents, as well as control measures in their long-term use.

Downloads

Download data is not yet available.

References

1. Каратеев Д. Е. Вопросы безопасности терапии ингибиторами ФНО / Д. Е. Каратеев // Соврем. ревматол. — 2009. — № 3. — С. 33—38.

2. Каратеев Д. Е. Современный взгляд на проблему быстропрогрессирующего ревматоидного артрита / Д. Е. Каратеев // Соврем. ревматол. — 2010. — № 2. — С. 37—42.

3. Сигидин Я. А., Лукина Г. В. Биологическая терапия в ревматологии / Я. А. Сигидин, Г. В. Лукина. — [2-е изд., доп.]. — М. : Практическая медицина, 2009. — 245 с.

4. Застосування антагоністів фактора некрозу пухлин в лікуванні хворих на ревматичні захворювання суглобів (ревматоїдний артрит, анкілозивний спондилоартрит, псоріатична артропатія): Метод. рекомендації / [Коваленко В. М., Шуба Н. М., Борткевич О. П. та ін.]. — Київ, 2008. — 40 с.

5. Коваленко В. М. Сучасні аспекти діагностики ревматоїдного артриту / В. М. Коваленко, О. П. Борткевич, Ю. В. Білявська // Здоров’я України. — 2010. — № 1 (березень). — С. 74—77.

6. Bergman M., Furfaro N. Individualizing therapy for rheumatoid arthritis: New strategies for maximizing treatment outcomes / M. Bergman, N. Furfaro // 2010 PCE Updates in Rheumatology. — 2010. — № 3 (2). — Р. 1—12.

7. Лучихина Е. Л. Ритуксимаб в современной терапии ревматоидного артрита / Е. Л. Лучихина // Соврем. ревматол. — 2008. — № 2. — С. 74—79.

8. Cohen S. B. REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to antitumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks / S. B. Cohen, P. Emery, M. W. Greenwald [et al.] // Arthritis Rheum. — 2006. — № 54. — Р. 2793—2806.

9. Emery P. The Efficacy and Safety of Rituximab in Patients With Active Rheumatoid Arthritis Despite Methotrexate Treatment Results of a Phase IIb Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial / P. Emery, R. Fleischmann, A. Fillipowicz-Sosnowska [et al.] // Arthritis Rheum. — 2006. — № 54 (5). — Р. 1390—1400.

10. Насонов Е. Л. Фармакотерапия ревматоидного артрита в эру генно-инженерных биологических препаратов / Е. Л. Насонов // Терапевт. арх. — 2007. — № 5. — С. 5—8.

11. Насонов Е. Л. Ритуксимаб в лечении ревматических болезней / Е. Л. Насонов // Науч.-практич. ревматол. — 2008. — № 2 (прил. 1). — С. 3–10.

12. Keystone E. Safety and Efficacy of Additional Courses of Rituximab in Patients With Active Rheumatoid Arthritis. An Open-Label Extension Analysis / E. Keystone, R. Fleischmann, P. Emery // Arthritis Rheum. — 2007. — № 56 (12). — Р. 3896—3908.

13. Kremer J. M. Repeat treatment with rituximab in active RA patients: long-term efficacy in patients with one versus two or more prior TNF inhibitors / J. M. Kremer, H. P. Tony, M. C. Genovese [et al.] // Ann. Rheum. Dis. — 2007. — № 66 (Suppl). — Р. 432.

14. Mease P. J. B Cell-Targeted Therapy in Autoimmune Disease: Rationale, Mechanisms, and Clinical Application / P. J. Mease // J. Rheumatol. — 2008. — № 35. — Р. 1245—1255.

15. Tak P. P. Inhibition of joint damage and improved clinical outcomes with a combination of rituximab (RTX) and methotrexate (MTX) in patients (pts) with early active rheumatoid arthritis (RA) who are naïve to MTX: a randomised active comparator placebo-controlled trial [abstract] / P. P. Tak, W. Rigby, A. Rubbert [et al.] // Ann. Rheum. Dis. — 2009. — № 68 (Suppl. 3). — Р. 75.

16. Genovese M. C. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition / M. C. Genovese, J. C. Becker, M. Schiff [et al.] // N. Engl. J. Med. — 2005. — № 353. — Р. 1114—1123.

17. Genovese M. C. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy / M. C. Genovese, M. Schiff, M. Luggen [et al.] // Ann. Rheum. Dis. — 2008. — № 67. — Р. 547—554.

18. Westhovens R. Disease remission is achieved within two years in over half of methotrexate naіve patients with early erosive rheumatoid arthritis (RA) treated with abatacept plus MTX: results from the AGREE Trial [abstract] / R. Westhovens, M. Robles, S. Nayiager [et al.] // Arthritis Rheum. — 2009. — № 60 (Suppl. 10). — Р. 638.

19. Westhovens R. Clinical efficacy and safety of abatacept in methotrexate-naпve patients with early rheumatoid arthritis and poor prognostic factors / R. Westhovens, M. Robles, A. C. Ximenes [et al.] // Ann Rheum Dis. — 2009. — № 68. — Р. 1870—1877.

20. Deighton C. Management of rheumatoid arthritis: summary of NICE guidance / C. Deighton, R. O’Mahony, J. Tosh [et al.] // BMJ. — 2009. — № 338. — b702.

21. Blom M., Kievit W., Fransen J. The reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritis / М. Blom, W. Kievit, J. Fransen [et al.] // J. Rheumatol. — 2009. — № 36. — Р. 2171—2177.

22. Emery P. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial / P. Emery, F. C. Breedveld, S. Hall [et al.] // Lancet. — 2008. — № 372. — Р. 375—382.

23. Hetland M. L. All Departments of Rheumatology in Denmark. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry / M. L. Hetland, I. J. Christensen, U. Tarp [et al.] // Arthritis Rheum. — 2010. — № 62. — Р. 22—32.

24. Hyrich K. L. British Society for Rheumatology Biologics Register. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study / K. L. Hyrich, M. Lunt, K. D. Watson [et al.] // Arthritis Rheum. — 2007. — № 56. — Р. 13—20.

25. Karlsson J. A. Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register / J. A. Karlsson, L. E. Kristensen, M. C. Kapetanovic [et al.] // Rheumatology (Oxford). — 2008. — № 47. — Р. 507—513.

26. Østergaard M. Low remission rates but long drug survival in rheumatoid arthritis patients treated with infliximab or etanercept: results from the nationwide Danish DANBIOdatabase / M. Østergaard, J. Unkerskov, L. Linde [et al.] // Scand J. Rheumatol. — 2007. — № 36. — Р. 151—154.

27. Pincus T. Why are only 50 % of courses of anti-tumor necrosis factor agents continued for only 2 years in some setting? Need for longterm observations in standart care to complement clinical trials / T. Pincus, Y. Yazici, R. van Vollenhoven // J. Rheumatol. — 2006. — № 33. — Р. 2372—2375.

28. Rubbert-Roth A., Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review / A. Rubbert-Roth, A. Finckh // Arthritis Res. Ther. — 2009. — № 11 (Suppl. 1). — S1.

29. Saag K. G. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis / K. G. Saag, G. G. Teng, N. M. Patkar [et al.] // Arthritis Rheum. — 2008. — № 59. — Р. 762—784.

30. Scrivo R. Switching between TNFalpha antagonists in rheumatoid arthritis: personal experience and review of the literature / R. Scrivo, F. Conti, F. R. Spinelli [et al.] // Reumatismo. — 2009. — № 61. — Р. 107—117.

31. Smolen J. S. GO-AFTER study investigators Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosisin patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial / J. S. Smolen, J. Kay, M. K. Doyle [et al.] // Lancet. — 2009. — № 374. — Р. 210—221.

32. Soubrier M. Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial / M. Soubrier, X. Puechal, J. Sibilia [et al.] // Rheumatology (Oxford). — 2009. — № 48. — Р. 1429—1434.

33. Насонов Е. Л. Новые возможности фармакотерапии ревматических болезней — ингибирование интерлейкина-6 / Е. Л. Насонов // Клин. фармакол. тер. — 2008. — № 1. — С. 60—67.

34. Emery P. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial / P. Emery, E. Keystone, H. P. Tony [et al.] // Ann. Rheum. Dis. — 2008. — № 67. — Р. 1516—1523.

35. Nishimoto N., Kishimoto T. Interleukin 6, from bench to bedside / N. Nishimoto, T. Kishimoto // Nat. Clin. Praс. Rheumatol. — 2006. — № 11. — Р. 619—626.

36. Bone H. G. Effects of Denosumab on bone mineral density and bone turnover in postmenopausal women / H. G. Bone, M. A. Bolognese, C. K. Yuen // J. Clin. Endocrinol. Metab. — 2008. — № 93 (6). — Р. 2149—2157.

37. Brown J. P. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomised, blinded, Phase 3 trial / J. P. Brown, R. L. Prince, Deal Chad [et al.] // J. Bone Mineral Res. —2009. — № 24. — Р. 153—161.

38. Cummings S. R. Denosumab for prevention of fractures in postmenopausal women with osteoporosis / S. R. Cummings, J. San Martin, M. R. McClung [et al.] // N Engl J Med. — 2009. — № 361. — Р. 756—765.

39. Delmas P. Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases / P. Delmas // J. Clin Densitometry: assessment of skeletal health. —2008. — Vol. 11 (2). — P. 325—338.

40. Geusens P. Emerging treatments for postmenopausal osteoporosis — focus on denosumab / P. Geusens // Clenical Interventions in ageing. — 2009. — № 4. — Р. 241—250.

41. Lewiecki E. M. Denosumab for the treatment of postmenopausal osteoporosis / E. M. Lewiecki // Women’s Health. — 2009. — № 5 (1). — Р. 15—22.

42. Lewecki E. M. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD / E. M. Lewecki, P. D. Miller, M. R. McClung [еt al.] // J. Bone Miner Res. — 2007. — № 22. — Р. 1832—1841.

43. Miller P. D. Effect of Denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy; a randomized blinded phase 2 clinical trial / P. D. Miller, M. A. Bolognese, E M. Lewiecki [et al.] // Bone. — 2008. — № 3. — Р. 222—229.

44. Miller P. D. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD / P. D. Miller, M. R. McClung [еt al.] // J. Bone Miner Res. —2007. — № 2. — Р. 1832—1841.

45. McClung M. R. Denosumab in Postmenopausal women with low bone mineral density / M. R. McClung, E. M. Lewiecki, B. C. Staneley // N Engl J Med. — 2006. — № 354. — Р. 821—831.

46. Van Vollenhoven R. F. Treatment of rheumatoid arthritis: state of the art 2009 / R. F. van Vollenhoven // Nat. Rev. Rheumatol. — 2009. — № 5. — Р. 531—541.

47. Furst D. E. Building towards a consensus for the use of tumour necrosis factor blocking agents / D. E. Furst, F. C. Breedveld, J. R. Kalden [et al.] // Ann Rheum Dis Dec. — 1999. — № 58. —
Р. 725—726.
How to Cite
Lysenko, N. V., & Kartvelishvili, A. Y. (1). BIOLOGICAL AGENTS IN MEDICAL THERAPY. The Journal of V. N. Karazin Kharkiv National University, Series "Medicine", (24), 81-90. Retrieved from https://periodicals.karazin.ua/medicine/article/view/6713
Section
Reviews